Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers

被引：0
|
作者：
Jazieh, Khalid
Tsai, Jill
Solomon, Sheila R.
Xie, Hao
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Guardant Hlth, Redwood City, CA USA
[3] Guardant Hlth Inc, Redwood City, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3519
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A case description of pulmonary enteric adenocarcinoma with KRAS G12D mutation
    Fan, Fan
    Zhang, Haijun
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (12) : 8787 - 8792
  • [22] Non-clinical identification and characterization of KRAS G12D inhibitors
    Brooun, A.
    Bae, J. H.
    Chen, H.
    Li, P.
    Lin, B.
    Fagan, P.
    Irimia, A.
    Nevarez, R.
    Zhang, J.
    Chen, P.
    Olaharski, D.
    Chiang, G.
    Vernier, J. M.
    Shoemaker, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S19 - S19
  • [23] A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
    Miyamoto-Sato, Etsuko
    Imanishi, Satoshi
    Huang, Lijuan
    Itakura, Shoko
    Iwasaki, Yoichi
    Ishizaka, Masamichi
    MOLECULES, 2023, 28 (14):
  • [24] SELECTIVE AFFINITY-ENHANCED T CELL RECEPTOR BISPECIFIC TARGETING OF KRAS G12D NEOANTIGEN DRIVEN CANCERS
    Whale, Andrew
    Poole, Andrew
    Karuppiah, Vijaykumar
    Hartt, Annabelle
    Haidar, Jaafar
    Moureau, Sylvie
    Lin, Aimee Bence
    Van der Kamp, Marc
    Plowman, Gregory
    Vuidepot, Annelise
    Cole, David
    Chillakuri, Chandramouli
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A924 - A924
  • [25] Mosaic RASopathy due to KRAS variant G12D with segmental overgrowth and associated peripheral vascular malformations
    Schmidt, Vanessa Franziska
    Wieland, Ilse
    Wohlgemuth, Walter A.
    Ricke, Jens
    Wildgruber, Moritz
    Zenker, Martin
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2021, 185 (10) : 3122 - 3128
  • [26] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
    Zhou, C.
    Li, W.
    Song, Z.
    Zhang, Y.
    Zhang, Y.
    Huang, D.
    Yang, Z.
    Zhou, M.
    Mao, R.
    Huang, C.
    Li, X.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273
  • [27] ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models
    Nagashima, T.
    Inamura, K.
    Nishizono, Y.
    Suzuki, A.
    Tanaka, H.
    Yoshinari, T.
    Yamanaka, Y.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S30 - S30
  • [28] Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR
    Susana Olmedillas-López
    Dennis César Lévano-Linares
    Carmen Laura Aúz Alexandre
    Luz Vega-Clemente
    Edurne León Sánchez
    Alejandro Villagrasa
    Jaime Ruíz-Tovar
    Mariano García-Arranz
    Damián García-Olmo
    World Journal of Gastroenterology, 2017, (39) : 7087 - 7097
  • [29] Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer
    Huang, Ri
    Du, Hong
    Cheng, Liang
    Zhang, Peizhuo
    Meng, Fenghua
    Zhong, Zhiyuan
    ACTA BIOMATERIALIA, 2023, 168 : 529 - 539
  • [30] Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR
    Olmedillas-Lopez, Susana
    Cesar Levano-Linares, Dennis
    Auz Alexandre, Carmen Laura
    Vega-Clemente, Luz
    Leon Sanchez, Edurne
    Villagrasa, Alejandro
    Ruiz-Tovar, Jaime
    Garcia-Arranz, Mariano
    Garcia-Olmo, Damian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (39) : 7087 - 7097
12345